SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3027It has been a long road from 2012 to today, with some swing trades in between bumopgcw38/19/2020
3026I think MNTA will ensure that they have at least some interim data from the autoDewDiligence_on_SI-2/13/2018
3025Oh? I thought, per the read me first, they were initiating trials, but not repotuck-2/13/2018
3024Hard to say what could move the stock, but there are some readouts in the autoimDewDiligence_on_SI-2/13/2018
3023And TEVA was too optimistic: 40Mg Glatopa approved and launched. So telegraphedtuck-2/13/2018
3022Teva expects 2nd generic Copaxone circa April. Cheers, Tucktuck12/8/2018
3021Same news seems to be moving AKAO this morningSteve Lokness-1/30/2018
3020CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Incnigel bates-1/30/2018
3019CMS proposals on various topics out today. Of interest to MNTA - should they evtuck-11/16/2017
3018Musings on value of MNTA's technology: investorshub.advfn.comDewDiligence_on_SI-10/7/2017
3017Although a 40mg launch is technically "at risk," TEVA's remaining DewDiligence_on_SI-10/4/2017
3016Wasn't there a bit of patent life left? i.e. if Mylan were to launch this vtuck-10/4/2017
3015I'm pretty sure the only issue is whether the FDA approves a 40mg generic frDewDiligence_on_SI-10/4/2017
3014Any way of handicapping that outcome? And in the best case scenario of shared etuck-10/4/2017
3013The damage today is not as bad as it could have been because FDA hasn't yet DewDiligence_on_SI-10/4/2017
3012Re Mylan getting 20mg and 40mg before MNTA. Slept in a bit and missed the news tuck-10/4/2017
3011Musings re ABBV-AMGN Humira-FoB settlement: investorshub.advfn.com investorshubDewDiligence_on_SI-9/28/2017
3010MNTA ‘ReadMeFirst’ updated: 2017-2018 news flow; reasons to be optimistic; 1QDewDiligence_on_SI-5/14/2017
3009Looks like good entry point here. [graphic]hollyhunter-4/7/2017
3008Bad link in post I'm replying to; for latest MNTA 'ReadMeFirst' (conDewDiligence_on_SI-3/13/2017
3007MNTA ‘ReadMeFirst’ updated with many new/revised items on Copaxone, FoBs, and prDewDiligence_on_SI-3/12/2017
3006MNTA 2017-2018 news flow—updated for delay to 40mg-Glatopa approval and other maDewDiligence_on_SI-2/17/2017
3005MNTA 2017-2018 news flow (updated): siliconinvestor.comDewDiligence_on_SI-2/17/2017
3004Woot!mopgcw11/31/2017
3003MNTA's phase-3 trial for Humira FoB had switching arm—consistent with FDA (dDewDiligence_on_SI-1/18/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News